Who is sponsoring NCT03785275?

NCT03785275 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03785275?

Interventions in NCT03785275: gallium-68-exendin PET/CT.

What condition does NCT03785275 study?

NCT03785275 studies Type 1 Diabetes Mellitus.

Is NCT03785275 still recruiting?

NCT03785275 is currently terminated. Last updated 14 February 2022.

Last reviewed 2022-02-14 · How we verify

NCT03785275: GLP1-reg

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beta Cell Imaging in T1D Patients With a Different Glycemic Control

Terminated Last updated 14 February 2022

What this trial tests

trial testing gallium-68-exendin PET/CT in Type 1 Diabetes Mellitus in 16 participants. Terminated before completion.

Timeline

6 December 2017

Primary endpoint
9 November 2020

9 November 2020

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	16
Start date	6 December 2017
Primary completion	9 November 2020
Estimated completion	9 November 2020
Sites	1 location across Netherlands

Drugs / interventions tested

gallium-68-exendin PET/CT

Conditions studied

Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Type 1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to measure (residual) beta cell mass in type 1 diabetes (T1D) patients with stable near-normal and unstable glucose control using PET/CT imaging, to improve the understanding of the relation between beta cell mass and glycemic control in T1D.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.
Velikyan I, Eriksson O. · · 2020 · cited 24× · PMID 31903131 · DOI 10.7150/thno.38366
Importance of beta cell mass for glycaemic control in people with type 1 diabetes.
Jansen TJP, Brom M, Boss M, Buitinga M, et al · · 2023 · cited 8× · PMID 36394644 · DOI 10.1007/s00125-022-05830-2

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes Mellitus

Currently open trials in the same condition.

NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03785275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03785275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing